Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday said the Phase 3 study of Keytruda plus Lenvima in combination with chemotherapy showed a statistically significant improvement in progression-free survival,

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese pharma giant’s tyrosine kinase inhibitor Lenvima for a certain type of cancer in the gastrointestinal tract.